The Measurement of Thyroid Absorbed dose by Gafchromic™ EBT2 Film and Changes in Thyroid Hormone Levels Following Radiotherapy in Patients with Breast Cancer

Abstract

Background: Radiotherapy is a main method for the treatment of breast cancer. This study aimed to measure the absorbed dose of thyroid gland using Gafchromic EBT2 film during breast cancer radiotherapy. In addition, the relationship between the absorbed dose and thyroid hormone levels was evaluated. Methods: Forty-six breast cancer patients, with the age ranged between 25 and 35 years, undergoing external radiotherapy were studied. The patients were treated with 6 and 18 MV X-ray beams, and the absorbed thyroid dose was measured by EBT2 film. Thyroid hormone levels, thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxin (T4), were measured before and after the radiotherapy. Pearson’s, Spearman’s, and Chi-square tests were performed to evaluate the correlation between the thyroid dose and hormone levels. Results: The mean thyroid dose was 26 ± 9.45 cGy with the range of 7.85–48.35 cGy. There were not any significant differences at thyroid hormone levels between preradiotherapy and postradiotherapy (P > 0.05). There was a significant relationship between increased thyroid absorbed dose and changes in TSH and T4 levels (P < 0.05), but it was not significant in T3 level (P = 0.1). Conclusion: Regarding the results, the thyroid absorbed dose can have an effect on its function. Therefore, the thyroid gland should be considered as an organ at risk in breast cancer radiotherapy.

Keywords: Breast cancer, Gafchromic film, radiotherapy, thyroid gland

Introduction

Breast cancer is one of the most common types of cancer among women worldwide.1,2 There are some methods for the treatment of breast cancer, including surgery, radiotherapy, chemotherapy, and hormone therapy.1,3,4 Given the long-term advantages, radiotherapy has been assessed as the primary treatment modality in most clinics for breast cancer.1,2,5 In this modality, ionizing radiation can destroy the cancerous cells or change the genes to terminate cellular growth.6

Although technological advances have led to major improvements in the radiation therapy of breast cancer, adverse effects such as increased exposure to ionizing radiation have been reported during the process of treatment of benign and malignant tumors.5,6

Radiation dose measurements of out-of-field organs, including lung, heart, ipsilateral breast and thyroid as organ at risk (OARs), during breast radiotherapy are crucial.7,8 Thyroid is one of the OARs during breast cancer radiotherapy; therefore, the probability of malignancies in this organ increases the following radiotherapy.8,9,10 Several studies have shown that there are some dosimetric devices for measuring radiotherapy doses.11-13 Gafchromic™ films have lots of advantages, and they are widely used in radiotherapy, for example, to verify treatment planning systems and evaluate two-dimensional absorbed dose maps.11-15

In a study, Kourinou et al.11 investigated the scattered out-of-field dose in some OARs such as thyroid, lungs, and breast during head-and-neck radiotherapy with thermoluminescent dosimeter (TLD). In another study by Lee et al.,7 the secondary cancer risk of breast cancer radiotherapy in some OARs including thyroid, brain, and...
eyes were evaluated by TLD dosimeter and also compared in different radiotherapy techniques.

Subclinical thyroid disease is defined by high or low serum concentrations of thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxin (T4), and they have a quite wide range due to analytical and biological variation in human; therefore, the assessment of hormone changes during radiation and subsequent to it, is very important.[16]

Due to the lack of studies on the thyroid absorbed dose by EBT2 films as a high sensitivity dosimeter, the current study aimed to measure the thyroid absorbed dose using EBT2 films during radiotherapy and to evaluate subsequent thyroid function in 46 breast cancer patients.

Materials and Methods

Gafchromic™ EBT2 film, irradiation, and calibration process

In the present study, Gafchromic™ EBT2 (International Specialty Products, Wayne, NJ, USA) film with dimensions of 8 × 10 inch was used. EBT2 films have several advantages compared to the previous ones, including better spatial resolution, energy and dose rate independence, density close to soft tissue or water, and less sensitivity to room light.[17-19] Furthermore, they do not need the conventional chemical processing and can be shaped to any phantoms.[16]

This type of film includes an active layer (30 µm), a thin topcoat (5 µm), and polyester substrate (175 µm). Furthermore, the coated layers are overlaminated with 50 µm polyester and a pressure-sensitive adhesive.[20]

The films were exposed using 6 MV X-rays from Varian linac 2100EX (Varian Medical Systems, Palo Alto, CA, USA). For the calibration process of the films, they were positioned at the depth of maximum absorbed dose in the slab phantom (PTW, Freiburg, Germany). Ten 30 cm × 30 cm × 1 cm acrylic sheets were set underneath the films.[21] Irradiation was done using 10 cm × 10 cm field at a source to surface distance of 100 cm. In addition, to validate the data obtained by a film, a farmer type 30,013 ionization chamber with sensitive volume of 0.6 cc (PTW, Freiburg, Germany) was used at the same condition of the film irradiation. All measurements were performed following the American Association of Physicists in Medicine Task Group-55 reports.[22]

Scanning and analysis of the films

To obtain the calibration curve, the film pieces were irradiated with different dose levels as follows: 25, 50, 100, 150, 200, 250, and 300 cGy to plot the calibration curve.

The films were cut into pieces of dimensions 2 cm × 3 cm and marked to indicate the film orientation. Furthermore, to evaluate the statistical error, three pieces of the film were randomly used for each radiation dose. Three unexposed film pieces were used to obtain the background fog.

The irradiated films were scanned with the Microtek 9800XL scanner (Microtek Inc. Santa Fe Spring, CA, USA) 48 h after irradiation, to stabilize the color, in the landscape mode.[23] All of the films were scanned with a 127-dpi spatial resolution in transmission scan mode in three colors, 48 bit RGB, and images were stored in Tagged Image File Format.

The scanned images were entered into ImageJ software (National Institutes of Health, Bethesda, Maryland), and the pixel values of the images were measured. About 2016 pixels (6 mm × 21 mm), located in the center of the films, were selected, and the mean value was calculated. Finally, the calibration (dose-response) curve of films was obtained based on the proposed method by Devic.[23]

Patient selection and treatment planning

Forty-six consecutive women with breast cancer (T1b-T3 stages and node-positive) undergoing breast-conserving surgery were incorporated in this study from February to December 2018. The average age of patients was 32 years (25–35 years), and the majority of the cohort (37 patients; 80.4%) had left-sided breast cancer. The patients were referred to Reza Radiation Oncology Center (Mashhad, Iran). The images for planning were obtained by a computed tomography (CT) scanner (Siemens Somatom Plus16; Siemens Healthineers, Munich, Germany) in the standard supine position during free breathing.

Radiation sensitive organs including lungs, spinal cord, larynx, heart, and thyroid gland, the gross tumor volume (GTV) and clinical tumor volume (CTV) were contoured by a radiation oncologist on the CT images. The planning target volume (PTV) was contoured regarding the borders proposed by the guidelines of the Radiation Therapy Oncology Group (RTOG) on the CT slices.[24] RT Dose PLAN treatment planning system (Math Resolutions, Columbia, USA) was used for three-dimensional conformal radiotherapy planning of patients.

In our study, all of the patients underwent partial breast surgery; therefore, there was no GTV, and the whole breast considered as CTV. The PTV consisted of the CTV plus a 5-mm margin to consider breathing motion and treatment setup uncertainties, and the borders of the PTV were chosen regarding the borders proposed by the guidelines of the RTOG.[24]

The 50 Gy prescribed dose was delivered to the patients in 25 fractions. The patients were irradiated by 6 and 18 MV X-rays using Varian Clinac 2100EX linear accelerator.

Two opposed tangential fields (medial and lateral) were planned to encompass the breast. Furthermore, two supraclavicular fields (anterior and posterior) were used to deliver the prescribed dose to the level I-II and supraclavicular lymph nodes [Figure 1]. Different weighing of the anterior and posterior fields was used to attain higher homogeneity and conformity. Wedges (15°) were used to...
improve the dose homogeneity. Dose-volume histograms were assessed to control the PTV coverage and OARs dosimetric parameters of each plan.

Thyroid surface absorbed dose measurement

The thyroid region for each patient was marked based on the CT images by an oncologist. The EBT2 film pieces were placed at three or four different positions (based on the thyroid size) on the neck for measuring thyroid surface absorbed dose. The scanned image of exposed film pieces was entered into ImageJ software to obtain the absorbed dose regarding the obtained calibration curve.

Evaluation of thyroid function

Thyroid function before and after radiotherapy (3 months later) was evaluated by measuring TSH, T3, and T4 levels in 46 patients. Due to differences in laboratory ranges of the hormones, the relative values were calculated for statistical analyses and comparisons.

Statistical analysis

The correlation between the variables was evaluated using Pearson’s test, Spearman’s test, and t-test with version 11.5 of SPSS software (SPSS Inc., Chicago, Illinois, US). Furthermore, Chi-square test was performed to determine the significant of the correlations. \( P < 0.05 \) was considered as statistically significant.

Results

The mean thyroid volume was 10.2 cm\(^3\) (9.5–10.5). After obtaining the films’ calibration curve from optical density data of red channel of scanned images, thyroid gland absorbed dose was calculated. Figure 2 shows the thyroid mean absorbed dose of each patient in one treatment session. The mean thyroid absorbed dose was 26 ± 9.45 cGy with the range of 7.85–48.35 cGy. Furthermore, it is notable that the thyroid gland surface absorbed dose in 67% of patients was 20–40 cGy.

The mean levels of thyroid hormones before radiotherapy were as follows: TSH = 2.35 ± 1 µIU/mL (0.3–6.32), T3 = 1.35 ± 0.44 ng/mL (0.45–2.38), and T4 = 9.6 ± 1.7 µg/dL (3.9–12.3), and the same values after radiotherapy were as follows: TSH = 2.27 ± 0.91 µIU/mL (0.3–4.6), T3 = 1.36 ± 0.41 ng/mL (0.31–2.11), and T4 = 9.7 ± 2.1 µg/dL (1.57–12.5). According to obtained \( P \) value data from Chi-square test (0.686 for TSH, 0.152 for T3, and 0.146 for T4), there is not any correlation between the thyroid hormone levels before and after radiotherapy.

After radiotherapy, the mean level of TSH decreased, and the highest variation was 5.83 µIU/m, but the mean levels of T3 and T4 increased, and the maximum variations were 0.79 ng/mL and 7.86 µg/dL, respectively. Table 1 indicates the variations of the hormone levels in all patients.

There was a significant correlation between the absorbed dose and TSH (\( P = 0.03 \)) and T4 (\( P = 0.02 \)) levels. However, there was no significant correlation between the absorbed dose and the change of T3 level (\( P = 0.1 \)).

Discussion

Since in radiotherapy techniques, peripheral radiation can damage the out-of-field organs, the minimization of radiation-induced damages is a major concern in treatment planning.\(^8\)

One of the OARs during breast radiotherapy is thyroid gland.\(^7,11\) Thyroid cancer can occur after radiation incidence or during diagnostic and therapeutic procedures;\(^8,25\) therefore, the study of the dose received by this organ is an important issue.

In this study, we measured the thyroid absorbed dose, during radiotherapy, by EBT2 film in patients with breast cancer. Furthermore, thyroid hormone levels (TSH, T3, and T4) were compared before and after the radiotherapy.

Our results showed that the mean thyroid absorbed dose was 26 ± 9.45 cGy. Lee et al.\(^7\) and Momeni et al.\(^26\) measured the thyroid secondary cancer risk after breast cancer radiotherapy. In their researches, the mean thyroid absorbed dose was 5 cGy–1.3 cGy, respectively, obtained

---

**Figure 1:** Two opposed tangential and supraclavicular fields used in three-dimensional conformal radiotherapy of breast

**Figure 2:** Mean absorbed dose of thyroid of 46 studied patients in one-session treatment
Table 1: The variation of the thyroid hormone levels thyroid-stimulating hormone, triiodothyronine, and thyroxin before and after 3-month radiotherapy

| Patient | TSH (µIU/mL) | T3 (ng/mL) | T4 (µg/dL) | Patient | TSH (µIU/mL) | T3 (ng/mL) | T4 (µg/dL) |
|---------|-------------|------------|------------|---------|-------------|------------|------------|
| 1       | −0.19       | 0.102      | 0.91       | 24      | 1.37        | 0.01       | −1.75      |
| 2       | 0.94        | −0.62      | −5.6       | 25      | 0.02        | 0.07       | −1.24      |
| 3       | 0.07        | −0.51      | −3.56      | 26      | 1.44        | −0.04      | 0.35       |
| 4       | 0.8         | 0.09       | −1.62      | 27      | 0.3         | −0.65      | 0.13       |
| 5       | 0.07        | 0.13       | −2.09      | 28      | −0.06       | 0.33       | −0.8       |
| 6       | −2.15       | −0.73      | −2.27      | 29      | 0.62        | 0.2        | 1.42       |
| 7       | 0.37        | 0.46       | 1.45       | 30      | −0.06       | 0.19       | 0.71       |
| 8       | 5.83        | 0.38       | −0.83      | 31      | −0.23       | −0.29      | −0.87      |
| 9       | 0.03        | 0.29       | −0.73      | 32      | 0.8         | 0.08       | −1.69      |
| 10      | 2.15        | 0.24       | 0.7        | 33      | 0.28        | −0.09      | 1.85       |
| 11      | 0.19        | −0.79      | 0.68       | 34      | −0.27       | −0.18      | 1.17       |
| 12      | −0.25       | 0.14       | −0.8       | 35      | −0.26       | 0.32       | −1.53      |
| 13      | 0.69        | 0.49       | 2.4        | 36      | 0.23        | −0.14      | 1.47       |
| 14      | 0           | 0.09       | 1          | 37      | 0.02        | 0.4        | 0.9        |
| 15      | −0.6        | −0.1       | −0.8       | 38      | −0.43       | −0.39      | 1.3        |
| 16      | 0.6         | 0.66       | −0.9       | 39      | −0.19       | −0.13      | −1.32      |
| 17      | 0.06        | 0.02       | 0.66       | 40      | 0.04        | 0.14       | −2.5       |
| 18      | −0.43       | −0.25      | −0.6       | 41      | −0.45       | −0.13      | −0.5       |
| 19      | −0.09       | −0.14      | −1.52      | 42      | −0.52       | 0.3        | 4.66       |
| 20      | −0.24       | −0.25      | −1.15      | 43      | −0.15       | −0.17      | 0.78       |
| 21      | −0.15       | 0.06       | −0.55      | 44      | −0.53       | −0.11      | 3.04       |
| 22      | −1.03       | −0.56      | −2.47      | 45      | −1.45       | −0.16      | 1.33       |
| 23      | −1.49       | 0.07       | 0.18       | 46      | −0.44       | 0.54       | 7.86       |

TSH=Thyroid-stimulating hormone

There was a significant correlation between the absorbed dose and the TSH and T4 levels. Yoden et al. showed that there is a risk for hypothyroidism (high level of TSH and/or low level of T3 and/or T4) when thyroid received dose is ≥30 Gy, and also this risk is possible for thyroid dose ranges between 10 and 30 Gy. Other studies have reported that the relative risk of hypothyroidism is 40% for patients receiving 30-45 Gy and 12%-27% for those receiving less in patients treated for Hodgkin's disease. In our study, the mean total thyroid absorbed dose (at 25 sessions) was 6.5 ± 2.36 Gy; therefore, there is a potential risk of hypothyroidism.

Tunio et al. evaluated the dose distribution at the thyroid gland during breast cancer patients treated by supraclavicular radiotherapy technique. They expressed that the risk of hypothyroidism depends on the thyroid gland volume and follow-up duration and can be minimized using thyroid shield.

One of the limitations in our study was the short period thyroid hormones investigation after radiotherapy.

It is not entirely clear, the relationship between the absorbed dose values and thyroid hormones. Furthermore, considering the effect of different treatment techniques on thyroid dose values, the results of this study are not expandable to other treatment planning. Therefore, it is suggested that additional researches should be carried out with various treatment techniques to determine the correlation of absorbed dose, secondary cancer risks, and hormone level variations at thyroid gland during varying periods.
Conclusion

In the current study, the thyroid absorbed dose and variation of thyroid hormones attributable to breast irradiation were evaluated for 46 breast cancer patients. Our finding showed that there was a significant relationship between the increased thyroid absorbed dose, which measured using EBT2 films, and changes in TSH and T4 levels. Therefore, the thyroid gland should be considered as OARs in all breast cancer radiotherapies.

Acknowledgment

The authors would like to thank the Medical Physics Department at the Reza Radiation Oncology Center ( Mashhad, Iran) for their sincere cooperation.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

References

1. Firouzjah RA, Banaei A, Farhood B, Bakhshandeh M. Dosimetric comparison of four different techniques for supracavitary irradiation in 3D-conformal radiotherapy of breast cancer. Health Phys 2019;116:631-6.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebello M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
3. Chandwani KD, Perkins G, Nagendra HR, Raghuram NV, Spelman A, Nagarathna R, et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol 2014;32:10586-5.
4. Abdi Goushbolagh N, Abedi Firouzjah R, Ebrahimnejad Gorji K, Khorasani V, Moradi S, Banaei A, et al. Estimation of radiation dose-reduction factor for cerium oxide nanoparticles in MRC-5 human lung fibroblastic cells and MCF-7 breast-cancer cells. Artif Cells Nanomed Biotechnol 2018;46:SI215-25.
5. Brown LC, Mutter RW, Halyard MY. Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health 2015;7:449-58.
6. Jensen PT, Groenmold V, Klee MC, Thanov J, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2003;56:937-49.
7. Lee B, Lee S, Sung J, Yoon M. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT. J Radiat Prot 2014;34:325-31.
8. Schonfeld SJ, Lee C, Berrington de Gonzalez A. Medical exposure to radiation and thyroid cancer. Clin Oncol (R Coll Radiol) 2011;23:244-50.
9. van Asselen B, Raaijmakers CP, Hofman P, Lagendijk JJ. An improved breast irradiation technique using three-dimensional geometrical information and intensity modulation. Radiother Oncol 2001;58:341-7.
10. ICRU, “Prescribing, Recording and Reporting Photon Beam Therapy.” Report 50, International Commission on Radiation Units and Measurements, Bethesda, Md, USA, 1999.
11. Kourinou KM, Maznakis M, Lyaraki E, Stratakis J, Damilakis J. Scattered dose to radiosensitive organs and associated risk for cancer development from head and neck radiotherapy in pediatric patients. Phys Med 2013;29:650-5.
12. Abedi Firouzjah R, Nickfarjam A, Bakhshandeh M, Farhood B. The use of EBT3 film and Delta4 for the dosimetric verification of EclipseTm treatment planning system in a heterogeneous chest phantom: An IMRT technique. Int J Radiat Res 2019;17:355-61.
13. Chandraraj V, Stathakis S, Manickam R, Esquivel C, Supe SS, Papanikolaou N. Comparison of four commercial devices for rapidArc and sliding window IMRT QA. J Appl Clin Med Phys 2011;12:3367.
14. Massillon JL, Muñoz-Molina ID, Diaz-Aguirre P. Optimum absorbed dose versus energy response of Gafchromic EBT2 and EBT3 films exposed to 20–160 kV X-rays and 60Co gamma. Biomed Phys Eng Express 2010;6:045005.
15. Abedi Firouzjah R, Nickfarjam A, Bakhshandeh M. A comparison between GafchromicTm EBT3 film and Delta4® phantom in IMRT technique of a heterogeneous chest phantom. SSU J 2018;26:177-87.
16. Alterio D, Jereczek-Fossa BA, Franchi B, D’Onofrio A, Piazzii V, Rondi E, et al. Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: A retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys 2007;67:144-50.
17. Jung H, Kim O, Han Y, Park B, Cheong KH. Photon beam dosimetry with EBT3 film in heterogeneous regions: Application to the evaluation of dose-calculation algorithms. J Korean Phys Soc 2014;65:1829-38.
18. Sim GS, Wong JH, Ng KH. The use of radiochromic EBT2 film for the quality assurance and dosimetric verification of 3D conformal radiotherapy using microtek scanMaker 9800XL flatbed scanner. J Appl Clin Med Phys 2013;14:4182.
19. El Barouky J, Fournier-Bidoz N, Mazal A, Fares G, Rosenwald JC. Practical use of gafchromic(®) EBT films in electron beams for in-phantom dose distribution measurements and monitor units verification. Phys Med 2011;27:81-8.
20. Aland T, Kairn T, Jenny K. Evaluation of a gafchromic EBT2 film dosimetry system for radiotherapy quality assurance. Australas Phys Eng Sci Med 2011;34:251-60.
21. Arjomandy B, Tailor R, Anand A, Sahoo N, Gillin M, Prado K, et al. Energy dependence and dose response of gafchromic EBT2 film over a wide range of photon, electron, and proton beam energies. Med Phys 2010;37:1942-7.
22. Niroomand-Rad A, Blackwell CR, Coursey BM, Gall KP, Galvin JM, McLaughlin WL, et al. Radiochromic film dosimetry: Recommendations of AAPM radiation therapy committee task group 55. American Association of Physicists in Medicine. Med Phys 1998;25:2093-115.
23. Devic S. Radiochromic film dosimetry: Past, present, and future. Phys Med 2011;27:122-34.
24. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC) Int J Radiat Oncol Biol Phys 1995;31:1341-6.
25. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: The individual dosage of radioiodine. Endocr Relat Cancer 2010;17:R161-72.
26. Momeni Z, Tavakoli MB, Atarod M. Estimation of the thyroid gland absorbed dose during breast radiotherapy in 3D-conformal radiotherapy of breast cancer. Health Phys 2012;102:170-4.
27. Mentzel T, Schildhaus HU, Palmegio R, Stützer R, Kutzner H. Postirradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control
cases: Clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 2012;25:75-85.
28. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers athheroprotection on female mice. Science 2004;306:1954-7.
29. Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in apoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006;168:649-58.
30. Yoden E, Soejima T, Maruta T, Demizu Y, Nishimura H, Ejima Y, et al. Hypothyroidism after radiotherapy to the neck. Nihon Igaku Hoshasen Gakkai Zasshi Nippon Acta Radiol 2004;64:146‑50.
31. Kuten A, Lubochitski R, Fishman G, Dale J, Stein ME. Postradiotherapy hypothyroidism: Radiation dose response and chemotherapeutic radiosensitization at less than 40 gy. J Surg Oncol 1996;61:281-3.
32. Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation. Int J Radiat Oncol Biol Phys 1995;31:1165-70.
33. Tunio MA, Al Asiri M, Bayouni Y, Stanciu LG, Al Johani N, Al Saeed EF. Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study. J Cancer Res Ther 2015;11:684‑9.

BIOGRAPHIES

Leyla Ansari obtained her B.Sc. degree in Physics from Yasuj University, Iran, in 2012. She has received her M.Sc. degree in Medical Physics in 2016 from Shiraz University of Medical Sciences, Iran. She is currently a Ph.D. student at Iran University of Medical Sciences in Medical Physics. Her research interests are focused on Radiotherapy, Monte Carlo simulation, and image processing.

Email: leiliansaari1985@gmail.com

Neda Nasiri received her B.Sc. degree in 2013 and M.Sc. degree in 2018 in Medical Radiation Engineering from Science and Research Islamic Azad University, Iran. She is currently working as a nuclear medicine expert and studying at Ph.D. degree in Medical Radiation Engineering. Her research interests are Radiotherapy Physics and Ionizing Radiation Dosimetry.

Email: Nedann.1990@gmail.com

Fahimeh Aminolroayaei has obtained her B.Sc. degree in 2014 in Radiology Technology from Tehran University of Medical Sciences, Iran. She is received her M.Sc. degree in Medical Physics from Kashan University of Medical Sciences in 2017. Her research interests include Radiotherapy and Medical Imaging.

Email: aminolroayaeif@gmail.com

Karim Ghazikhanlou Sani received his B.Sc. degree in Radiology Technology from Tabriz University of Medical Sciences, Iran, in 2002. Also he has obtained his M.Sc. degree from Mashhad University of Medical Sciences in 2005, and Ph.D. degree from Tarbiat Modares University, Iran, in 2014 (both in Medical Physics). He is currently an Assistant Professor in Radiology Department of Hamadan University of Medical Sciences, Iran.

Email: Ghazi1356@gmail.com

Masoumeh Dorri-Giv has received her B.Sc. degree in 2013 in Radiology Technology and M.Sc. degree in Radiobiology in 2016 (both in Sahid Beheshti University of Meical Sciences, Iran). Her research interests are focused on Dosimetry, Treatment Planning in Radiotherapy, and Image processing.

Email: ma.dorrigiv@yahoo.com

Razzagh Abedi-Firouzjah obtained his B.Sc. degree in Radiology Technology from Babol University of Medical Sciences, Iran, in 2012 and his M.Sc. degree in Medical Physics from Shahid Sadoughi University of Medical Sciences, Iran, in 2017. His main areas of research interest are Radiotherapy Physics, Ionizing Radiation Dosimetry, Radiotherapy and CT scan techniques optimization, and Radiobiology.

Email: razzaghabedi@gmail.com

Dariush Sardari has obtained his B.Sc. degree from Isfahan University of Technology in 1989 and his M.Sc. degree in 1992 from Sharif University of Technology (both in Electrical Engineering). He has received his Ph.D. degree in Nuclear Physics in 1997 from Imperial College London (UK). He is currently a full professor at Science and Research Branch in Tehran. His research interests include photon and charge particle detection, Ionizing Radiation Dosimetry, and Monte Carlo simulation.

Email: Dsardari@hotmail.com